MENU
JUN 20, 2019 1:30 PM PDT

Introducing the therascreen FGFR RGQ RT-PCR Kit and Day-One Readiness at Insight Molecular Labs

Sponsored by: QIAGEN
C.E. Credits: P.A.C.E. CE Florida CE
Speakers
  • Chief Operating Officer, Insight Genetics
    Biography
      Dr. Hout is the Chief Operating Officer at the Nashville, TN based diagnostic company, Insight Genetics, Inc.

      Dr. Hout received his Ph.D. in molecular virology and has more than 15 years of assay development and design experience throughout his tenure.

      Dr. Hout has published and presented extensively on the development, validation, and performance of both qPCR and Next Generation sequencing clinical assays in peer reviewed journals and at national meetings.

      He is also board certified as a licensed Laboratory Supervisor and has extensive experience with both CLIA and CAP compliance.
    • Global Product Manager, Oncology & Precision Diagnostics, QIAGEN
      Biography
        Ben is a member of the Oncology Diagnostics Global Product Management team at QIAGEN, with responsibility for commercialisation of innovative new Companion Diagnostic tests around the world, including the therascreen FGFR RGQ RT-PCR Kit recently approved by the FDA in the USA.

        A molecular biologist and immunologist by qualification, he has over a decade of experience in the IVD industry covering a range of roles including assay development, manufacturing and product management.

        He is based in Manchester, UK, the QIAGEN global centre of excellence for companion diagnostic development, where the FGFR RGQ RT-PCR Kit was originally developed.

      Abstract

      The practice of precision medicine utilizes advanced diagnostic tools to identify specific groups of patients on the basis of particular molecular characteristics, and guide their treatment with therapeutics that are selectively active against disease cases which harbor these characteristics. This approach is transforming the care that patients receive, particularly in oncology. In this presentation, Dr. Benjamin Chaffey and Dr. David Hout will firstly introduce the QIAGEN therascreen® FGFR RGQ RT-PCR Kit, which was recently co-approved by the FDA as the companion diagnostic test to guide prescription of BALVERSA™, a novel FGFR inhibitor, in cases of urothelial cancer. They will then describe how patient access to testing has been made available as rapidly as possible through Insight Genetics’ participation in the QIAGEN Day-One Readiness program for this test.

      Learning Objectives: 

      1. To gain a more complete understanding of the importance of FGFR testing when identifying treatment options for patients suffering with advanced urothelial cancer
      2. To learn how the Day-One Readiness program enables QIAGEN and partner labs such as Insight to accelerate the availability of innovative new tests to health care providers and thereby improve the quality of care which can be delivered to patients.


      Show Resources
      You May Also Like
      JAN 23, 2020 9:00 AM PST
      C.E. CREDITS
      JAN 23, 2020 9:00 AM PST
      DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
      APR 07, 2020 8:00 AM PDT
      C.E. CREDITS
      APR 07, 2020 8:00 AM PDT
      DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
      MAY 08, 2020 10:00 AM PDT
      C.E. CREDITS
      MAY 08, 2020 10:00 AM PDT
      DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
      FEB 26, 2020 9:00 AM PST
      C.E. CREDITS
      FEB 26, 2020 9:00 AM PST
      DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
      JUN 23, 2020 10:00 AM PDT
      C.E. CREDITS
      JUN 23, 2020 10:00 AM PDT
      DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
      JUN 17, 2020 1:30 PM PDT
      C.E. CREDITS
      JUN 17, 2020 1:30 PM PDT
      Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
      Loading Comments...
      Show Resources